Adarx Pharmaceuticals Raises $446.3 Million in Upsized US IPO
Why now
Thesis: Upsized biotech deal signals selective risk appetite
Catalyst to watch: Trading debut and analyst initiation
Main risk: Rate backdrop could sour follow-on demand
Why it matters
An upsized biotech IPO indicates investor demand for early-stage pharma risk despite rate pressure.
Sources
- googlenews · news.google.com · 2026-09-24 23:43 UTC
- googlenews · news.google.com · 2026-09-24 23:43 UTC
- googlenews · news.google.com · 2026-09-24 23:43 UTC